市場調査レポート
商品コード
1451731
抗てんかん薬市場:世代別、抗てんかん薬タイプ別、流通チャネル別、地域別、2024-2032Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
抗てんかん薬市場:世代別、抗てんかん薬タイプ別、流通チャネル別、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2~3営業日
|
抗てんかん薬の世界市場規模は2023年に23億米ドルに達しました。今後、IMARC Groupは、2024~2032年の成長率(CAGR)は7.16%で、2032年には44億米ドルに達すると予測しています。てんかんの有病率の上昇、老年人口における脳腫瘍の発生率の増加、広範な研究開発(R&D)活動は、市場を牽引する主な要因のひとつです。
抗てんかん薬とは、てんかんの治療に使用される薬剤のことであり、てんかんは、予測不能で、誘発性のない、再発性の発作を引き起こす中枢神経系(CNS)疾患です。てんかんは様々な精神的・身体的機能に影響を及ぼし、突然の行動変化、感覚、意識の喪失、深刻な精神的苦痛を引き起こします。抗てんかん薬には、錠剤、カプセル剤、液剤、シロップ剤などの第一世代、第二世代、第三世代の抗てんかん薬(AED)があり、経口投与、静脈内投与、筋肉内投与が行われています。抗てんかん薬は、部分発作、難治性発作、混合発作、強直間代発作、急性反復発作など、さまざまな発作の治療に広く用いられています。抗てんかん薬は安全で、忍容性が高く、生命を脅かす副作用を防ぎ、認知機能への悪影響を最小限に抑えることができます。
現在、神経疾患、出産関連傷害、感染症、薬物乱用、交通事故などの増加によりてんかんの有病率が上昇していることが、市場の成長を促す主な要因の一つとなっています。抗てんかん薬は、発作の除去、発作頻度の減少、長期治療に伴う副作用の回避のために広く使用されており、患者が通常の心理社会的・職業的活動を回復し、通常のライフスタイルを維持するのに役立っています。これに加えて、発作の原因となる脳腫瘍などの重大な病気を発症しやすい老年人口の増加が、もう一つの大きな成長促進要因として作用しています。さらに、手頃な価格で、副作用が少なく忍容性と有効性が改善された新薬や先進薬の開発に向けた広範な研究開発(R&D)活動は、現在、市場成長にプラスの影響を与えています。これとは別に、血清中薬物濃度の変動を最小限に抑えながら投与間隔を長くできる徐放性(ER)製剤が最近開発され、即放性(IR)製剤に比べて有効性と服薬アドヒアランスが向上したことが、市場の成長を促進しています。さらに、この疾患について大衆を啓蒙し、研究を促進し、より良い治療選択肢を迅速化することで積極的な支援を提供するための様々な政府イニシアチブの実施が、市場の成長を促進しています。その他にも、新薬の認可の高まり、ヘルスケアインフラ施設の急速な改善、神経疾患の利用可能な治療法に関する一般市民の意識の高まり、てんかんにまつわるスティグマの減少などが、市場の成長を後押しすると予測されています。
The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.
Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.
At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.
Generation Type Insights
First Generation Drugs
Phenytoin
Carbamazepine
Oxcarbazepine
Valproate
Ethosuximide
Primidone
Phenobarbital
Second Generation Drugs
Levetiracetam
Lamotrigine
Topiramate
Pregabalin
Rufinamide
Zonisamide
Third Generation Drugs
Lacosamide
Perampanel
Eslicarbazepine Acetate
Ezogabine/Retigabine
The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.
Anti-Epileptics Drugs Type Insights
Narrow-Spectrum AEDs
Broad-Spectrum AEDs
A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.
Distribution Channel Insights
Hospital Pharmacy
Pharmacy Stores
Others
A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report